VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 487 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2014. The put-call ratio across all filers is 0.91 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $2,346,000 | – | 135,201 | +13520000.0% | 0.01% | – |
| Q1 2017 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 1 | -100.0% | 0.00% | -100.0% |
| Q3 2015 | $5,975,000 | -44.5% | 33,500 | -30.9% | 0.03% | -40.4% |
| Q2 2015 | $10,774,000 | -7.3% | 48,500 | -17.1% | 0.05% | -7.8% |
| Q1 2015 | $11,619,000 | +0.2% | 58,500 | -27.8% | 0.05% | +2.0% |
| Q4 2014 | $11,592,000 | -45.5% | 81,000 | -50.0% | 0.05% | 0.0% |
| Q3 2014 | $21,254,000 | +23.9% | 162,000 | +19.1% | 0.05% | -34.2% |
| Q2 2014 | $17,152,000 | -19.5% | 136,000 | -15.9% | 0.08% | -20.8% |
| Q1 2014 | $21,317,000 | -32.3% | 161,700 | -39.7% | 0.10% | -32.4% |
| Q4 2013 | $31,475,000 | +18.8% | 268,100 | +5.6% | 0.14% | +21.4% |
| Q3 2013 | $26,500,000 | +146.3% | 254,000 | +103.2% | 0.12% | +154.3% |
| Q2 2013 | $10,760,000 | – | 125,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |